Human Reference Immune Globulin to Respiratory Syncytial Virus, CBER RSV Lot 1

Catalog No. NR-21973
This reagent is the property of the U.S. Government.

For research use only. Not for human use.

Contributor:
U.S. Food and Drug Administration

Manufacturer:
Baxter S.A., Lessines, Belgium

Product Description:
Human plasma was obtained from normal healthy donors, some of whom had probably been infected with respiratory syncytial virus (RSV) in the past. The immune globulin was purified from the plasma pools using a modified Cohn-Oncley cold ethanol fractionation process, as well as cation and anion exchange chromatography. The immune globulin was further treated to remove or inactivate viruses using solvent detergent treatment (with tri-n-butyl phosphate, octoxynol 9, and polysorbate 80 at 18°C to 25°C for a minimum of 60 minutes), 35 nm filtration and low pH incubation at an elevated temperature. The final immune globulin (10%) is a sterile 100 mg/mL protein preparation stabilized with 0.25 M glycine (pH 4.6 to 5.1). At least 98% of the protein was determined to be immune globulin. The osmolality was determined to be 240 to 300 mOsmol/kg.

Material Provided:
Each vial contains approximately 2 mL of immune globulin (10%) in 0.25 M glycine (pH 4.6 to 5.1).

Note: Dilute 1:10 to a final concentration of 1% immune globulin in sterile PBS (pH 7.4) prior to testing in virus neutralization assays.

Packaging/Storage:
NR-21973 was packaged aseptically in glass tubes. It is provided frozen and should be stored at -20°C or colder immediately upon arrival.

Citation:
Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Human Reference Immune Globulin to Respiratory Syncytial Virus, CBER RSV Lot 1, NR-21973.”

Biosafety Level: 1

Each individual plasma donation was tested using licensed serological tests for hepatitis B surface antigen (HBsAg) and for antibodies to human immunodeficiency virus (HIV-1/HIV-2) and hepatitis C virus (HCV) and found to be negative. As an additional safety measure, pools of plasma were tested using licensed nucleic acid tests for HIV-1 and HCV and found to be negative.

Universal Precautions should be used when handling biological materials derived from human sources, such as NR-21973.

Disclaimers:
You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:
This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

ATCC® is a trademark of the American Type Culture Collection.